Pharmacovigilance Evaluation Of Benefix (Registered) In Germany And Austria
Overview
- Phase
- Not Applicable
- Intervention
- BeneFIX
- Conditions
- Hemophilia B
- Sponsor
- Pfizer
- Enrollment
- 80
- Locations
- 21
- Primary Endpoint
- Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of this observational study is to describe the incidence of adverse events among patients treated with BeneFix® in usual health care settings in Germany.
Detailed Description
Non-interventional study: subjects to be selected according to the usual clinical practice of their physician
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with hemophilia B already receiving or starting treatment with reformulated BeneFIX®.
Exclusion Criteria
- •Patients with hemophilia B treated with a product other than BeneFIX®.
- •Inclusion in the ongoing prospective registry of European hemophilia B patients using BeneFIX®.
Arms & Interventions
A
Patients with Hemophilia B
Intervention: BeneFIX
Outcomes
Primary Outcomes
Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Baseline until last visit (up to 8.7 years)
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; cancer; congenital anomaly. AEs included both serious and non-serious. Relatedness to BeneFIX was assessed by the investigator.
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Baseline until last visit (up to 8.7 years)
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability or incapacity; cancer; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to last visit (up to 8.7 years) that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious.
Number of Participants With Factor IX (FIX) Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
Time Frame: Baseline until last visit (up to 8.7 years)
FIX inhibitor development was defined as measured inhibitor titer of greater than (\>) 0.6 Bethesda Units (BU) using the Nijmegen-modified Bethesda assay.
Number of Participants With Adverse Events (AEs) of Special Interest
Time Frame: Baseline until last visit (up to 8.7 years)
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Adverse Events of special interest included allergic reactions, less than expected therapeutic effect (LETE) of drug, lack of efficacy/low recovery, erythrocyte agglutination in tube or syringe red blood cell (RBC) agglutination phenomena and thrombogenicity.
Investigator Assessment of Treatment Tolerability of Participants
Time Frame: End of study visit (any time up to 8.7 years)
Investigator assessed the tolerability of participants and categorized as very good, good, moderate and poor.
Participant Assessment of Treatment Tolerability
Time Frame: End of study visit (any time up to 8.7 years)
Participants evaluated their treatment (BeneFIX) tolerability and rated it in 4 categories as very good, good, moderate and poor.
Secondary Outcomes
- Mean Total Number of Bleeding Episodes in Participants(Baseline until last visit (up to 8.7 years))
- Mean Total Number of Bleeding Episodes Per Year in Participants(Baseline until last visit (up to 8.7 years))
- Number of Participants With Change From Baseline Status in Number of Days Missed From School or Work(Baseline, up to 8.7 years)
- Investigator Assessment of Treatment Efficacy of Participants(End of study visit (any time up to 8.7 years))
- Investigator Assessment of Treatment Handling of Participants(End of study visit (any time up to 8.7 years))
- Assessment of Treatment Efficacy by the Participants(End of study visit (any time up to 8.7 years))
- Assessment of Treatment Handling by the Participants(End of study visit (any time up to 8.7 years))
- Investigator Assessment of Treatment Satisfaction of Participants(Baseline up to 8.7 years)